Nanobodies: The “Magic Bullets” in therapeutics, drug delivery and diagnostics
Authors:
- Manzoor A. MirManzoor A. Mir
- Umar MehrajUMUmar Mehraj
- Bashir Ahmad SheikhBSBashir Ahmad Sheikh
- Syed Suhail HamdaniSHSyed Suhail Hamdani
- 13 February 2020
- journal article
- review article
- Published by SAGE Publications in Human Antibodies
- Vol. 28 (1) , 29-51
Abstract
Antibodies represent a well-established class of clinical diagnostics for medical applications as well as essential research and biotechnological tools. Although both polyclonal and monoclonal antibodies are indispensable reagents in basic research and diagnostics but both of them have their limitations. Hence, there is urgent need to develop strategies aimed at production of alternative scaffolds and recombinant antibodies of smaller dimensions that could be easily produced, selected and manipulated. Unlike conventional antibodies, members of Camelidae and sharks produce antibodies composed only of heavy chains with small size, high solubility, thermal stability, refolding capacity and good tissue penetration in vivo. The discovery of these naturally occurring antibodies having only heavy-chain in Camelidae family and their further development into small recombinant nanobodies represents an attractive alternative in drug delivery, diagnostics and imaging. Nanobody derivatives are soluble, stable, versatile, have unique refolding capacities, reduced aggregation tendencies and high-target binding capabilities. They can be genetically customized to target enzymes, transmembrane proteins or molecular interactions. Their ability to recognize recessed antigenic sites has been attributed to their smaller size and the ability of the extended CDR3 loop to quickly penetrate into such epitopes. With the advent of molecular engineering and phage display technology, they can be of potential use in molecular imaging, drug delivery and therapeutics for several major diseases. In this review we present the recent advances in nanobodies for modulating immune functions, for targeting cancers, viruses, toxins and microbes as well as their utility as diagnostic and biosensor tools.Keywords
This publication has 162 references indexed in Scilit:
- IgG-Fc glycoengineering in non-mammalian expression hostsArchives of Biochemistry and Biophysics, 2012
- Single domain antibodies: promising experimental and therapeutic tools in infection and immunityMedical Microbiology and Immunology, 2009
- Crystal Structure of the N-Terminal Domain of the Secretin GspD from ETEC Determined with the Assistance of a NanobodyStructure, 2009
- Thermostable Llama Single Domain Antibodies for Detection of Botulinum A Neurotoxin ComplexAnalytical Chemistry, 2008
- Properties, production, and applications of camelid single-domain antibody fragmentsApplied Microbiology and Biotechnology, 2007
- Facile Generation of Heat-Stable Antiviral and Antitoxin Single Domain Antibodies from a Semisynthetic Llama LibraryAnalytical Chemistry, 2006
- Formatted anti–tumor necrosis factor α VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen‐induced arthritisArthritis & Rheumatism, 2006
- Engineered antibody fragments and the rise of single domainsNature Biotechnology, 2005
- Efficient tumor targeting by single‐domain antibody fragments of camelsInternational Journal of Cancer, 2002
- Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coliNature, 1989